Business
Hardman: Clinical development towards submission
Hardman: Clinical development towards submission.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8865G Allergy Therapeutics PLC 07 March 2018 \n\nHardman Research: Clinical development towards submission\nClinical development towards submission: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'Named Patient' basis. The Phase III trial, designed to obtain approval for PQ Birch as a biologic in Europe, is well advanced, and the Phase II PQ Grass trial will report data shortly. As explained in the February trading update, underlying 1H'18 sales growth, although weaker than expected due to a low pollen season in central Europe, suggests that AGY has continued to make market share gains.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/agy---interims---7th-march-2018.pdf\n\n\n\n\nTo contact us:\nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\nwww.hardmanandco.com \nFollow us on Twitter @HardmanandCo\n\n\nContacts:\nDr Martin Hall\nDr Dorothea Hill\nDr Gregoire Pave\n\n+44 20 7194 7622\n\n\n \[email protected]@[email protected]\n\n\n\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth...